{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/epistaxis-nosebleeds/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"4ac070a5-a9e9-58a1-a125-c8a457f1833a","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field 035f5246-f877-433c-b7a1-eb224346ed9a --><h2>How should I assess a person with acute epistaxis?</h2><!-- end field 035f5246-f877-433c-b7a1-eb224346ed9a -->","summary":"","htmlStringContent":"<!-- begin item 08794923-6480-4446-8988-07f99aaee344 --><!-- begin field ce0e694e-0a9e-47cc-bdbb-bdcbf84d175f --><ul><li><strong>Be aware that complications are most likely if bleeding is severe and/or the person is older, unwell, or frail. </strong><strong>Use clinical judgement to determine if it is necessary to assess the person's airway, breathing, pulse, and blood pressure. </strong>Also be aware of potential symptoms of haemodynamic compromise, including lightheadedness, syncope, and pallor.</li><li><strong>If the person exhibits signs and symptoms of compromise, arrange immediate transfer to Accident and Emergency. Use <a class=\"topic-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/management/acute-epistaxis/#management-of-acute-epistaxis\">first aid measures</a> while awaiting hospital transfer.</strong></li><li><strong>If the person is not haemodynamically compromised, ask:</strong><ul><li>When the bleeding started and from which nostril.</li><li>How much blood has been lost. This is difficult to estimate, but establish whether the bleeding is light or heavy. If bleeding is heavy, ask the person how many cups (each equates to approximately 250 mL) they think they have lost. Significant blood loss may necessitate admission to hospital.</li><li>Whether a temporary pack (such as cotton wool) has been used before seeking medical help. These are not always easily visible, and formal nasal packing can push foreign bodies further into the nose.</li><li>About any previous episodes of epistaxis and how they were treated.</li></ul></li><li><strong>Examine both nasal passages </strong>(ideally with adequate lighting and a nasal speculum).<ul><li>Where clinically appropriate, ask the person to gently blow the nose to clear old blood and large clots.</li><li>Look for a bleeding point. It will look like a small red dot (less than 1 mm) and may not be actively bleeding (note: active bleeding may prevent accurate assessment).</li></ul></li><li><strong>Suspect a posterior bleed </strong>if bleeding is profuse, from both nostrils, the bleeding site cannot be identified on speculum examination, and/or if bleeding first started down the throat (however, be aware that if bleeding commenced while the person was supine, blood is likely to have drained to the throat regardless of bleeding site).</li><li><strong>Determine if there may be an <a class=\"topic-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/background-information/causes/\">underlying cause</a>, </strong><strong>particularly in children younger than 2 years of age as epistaxis is unusual in this age group. Ask about/consider:</strong><ul><li><strong>A history of surgery or recent trauma (consider the possibility of non-accidental injury).</strong><ul><li>Be aware that epistaxis in children under the age of two years has been associated with intentional or non-intentional asphyxia. Features associated with asphyxiation for those with epistaxis include pallor, cyanosis, respiratory difficulty, altered heart rate, reduced consciousness, and a possible history of Apparent Life-Threatening Events. However, some children presenting with epistaxis due to asphyxia have no other overt symptoms. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/child-maltreatment-recognition-management/\">Child maltreatment - recognition and management</a>.</li></ul></li><li><strong>Symptoms suggestive of a tumour </strong>including nasal obstruction, rhinorrhoea, facial pain, hearing loss, persistent lymphadenopathy, and/or evidence of cranial neuropathy (for example facial numbness or double vision). Be aware that nasal, sinus, and nasopharyngeal cancers are most common in people older than 50 years of age, in those with occupational exposure to wood dust or chemicals, and (for nasopharyngeal cancer) in people of South Chinese or North African family origin.</li><li><strong>Other nasal symptoms that may be suggestive of allergic rhinitis or bacterial rhinosinusitis, nasal polyps, or nasal foreign body. </strong>For futher information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/sinusitis/\">Sinusitis</a> and <a class=\"topic-reference external-reference\" href=\"/topics/allergic-rhinitis/\">Allergic rhinitis</a>.</li><li><strong>Current medications </strong>(for example aspirin, warfarin, or nasally-administered drugs).<ul><li>If the person is taking warfarin, check the INR (international normalized ratio) or admit to hospital if bleeding is difficult to control.</li></ul></li><li><strong>Conditions predisposing to bleeding</strong> (such as haemophilia or leukaemia). For further information, please see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/haematological-cancers-recognition-referral/\">Haematological cancers - recognition and referral</a>.</li><li><strong>Symptoms or family history of bleeding disorders </strong>(such as hereditary haemorrhagic telangiectasia — suggested by red or purple spots on the fingertip pads, lips, lining of the nose, gut and occasionally the ears and face).</li><li><strong>Environmental factors </strong>(such as cold, dry weather, low humidity).</li></ul></li><li><strong>Laboratory investigations are not usually required unless an underlying cause is suspected:</strong><ul><li><strong>A full blood count </strong>should be considered if bleeding has been heavy or recurrent, or anaemia is suspected.</li><li><strong>Coagulation studies </strong>should be requested only if a clotting disorder is suspected or an INR is required.</li></ul></li></ul><!-- end field ce0e694e-0a9e-47cc-bdbb-bdcbf84d175f --><!-- end item 08794923-6480-4446-8988-07f99aaee344 -->","topic":{"id":"41f6c6fa-463d-5a28-9ffa-15f68320f0ad","topicId":"4e494407-5d2a-47b0-8980-124980c278b3","topicName":"Epistaxis (nosebleeds)","slug":"epistaxis-nosebleeds","lastRevised":"Last revised in August 2020","chapters":[{"id":"8924b1cb-1830-5e93-a601-5a515e1ef05c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"7267ef2e-a210-5137-a813-dac8e91b1831","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b0e06988-22ae-5f73-bb20-2033460ee20a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fb00e926-a8d3-5ae8-8f15-5dca94fff64d","slug":"changes","fullItemName":"Changes"},{"id":"a4dfa534-2e88-5962-97a7-50f5bc6903c5","slug":"update","fullItemName":"Update"}]},{"id":"182f787a-708c-5014-9591-48eddb54268d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bcaf0313-1bdc-548f-971f-dc9159fb2738","slug":"goals","fullItemName":"Goals"},{"id":"1820dda9-b7b1-5247-ad00-826f0b3f4c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6508b703-ccd2-56fe-b323-3dfd267f6057","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"27ddc66a-0532-592f-be80-40b6581b9e9c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d6beda29-ddc7-569c-8f25-2395cd0b3213","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9b9f6fbd-0722-5dcc-afac-e879fdfc6832","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1c7c7c7b-4f02-5cb0-af91-12ff20526fa7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6a3ef102-679b-5a9e-9d3d-73b58b70d2ef","slug":"definition","fullItemName":"Definition"},{"id":"05e8d25d-b629-5896-847e-76ab44c33576","slug":"causes","fullItemName":"Causes"},{"id":"7e0e17b8-b890-541e-92b5-0790ae3d08b5","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2624ce06-f85b-541e-a7bb-589ee1197b08","slug":"prognosis","fullItemName":"Prognosis"},{"id":"7f96f0b5-4a51-5413-b0b1-73ea61f581ac","slug":"complications","fullItemName":"Complications"}]},{"id":"eee7ea0d-538e-53b8-bf4c-3333153a7978","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ac070a5-a9e9-58a1-a125-c8a457f1833a","slug":"assessment","fullItemName":"Assessment"}]},{"id":"662dfd0d-d907-52ea-8d8b-97a3cf464cc7","fullItemName":"Management","slug":"management","subChapters":[{"id":"e0220daa-0b07-5f92-af4d-9530f90352ea","slug":"acute-epistaxis","fullItemName":"Scenario: Acute epistaxis"},{"id":"49c8979b-9af3-5eab-a574-05004fda4a4a","slug":"recurrent-epistaxis","fullItemName":"Scenario: Recurrent epistaxis"}]},{"id":"91147d78-80c8-5364-b3e1-7995b6718b2a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c7a65cbb-e7c2-50f8-b6a2-68a41e1db4cb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bb7e51c5-d888-5640-8c0b-07c8a505bf48","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3c48404f-ce42-5815-8d02-6dd6ef1ae5f3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b82f78a8-0e22-5156-bc34-baaa9c78ee15","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6093800a-eb2a-53e5-918a-e8f0be8c4ae0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6ce6588e-beaa-5a3b-a424-cfad9a225022","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1343761f-c431-50df-9bd2-a9b600c5e067","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"eee7ea0d-538e-53b8-bf4c-3333153a7978","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"a0200111-b3a0-584f-8f88-04b4ba782591","slug":"basis-for-recommendation-2c7","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 572b5d48-e56a-4322-acd0-6eb9dd17342b --><h3>Basis for recommendation</h3><!-- end field 572b5d48-e56a-4322-acd0-6eb9dd17342b -->","summary":null,"htmlStringContent":"<!-- begin item 2c7b9551-8b73-47c9-9b29-298728add8b6 --><!-- begin field 3266158b-4775-404a-89cf-5d7fc9665a48 --><p>The recommendations on assessment of a person with epistaxis are based on expert opinion within an American guideline <em>Epistaxis: an overview</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Kasperek and Pollock, 2013</a>], the BMJ Best Practice Guideline <em>Epistaxis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">BMJ Best Practice, 2018</a>], and a number of narrative review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Pashen and Stevens, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Wormald, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Crown and Criner, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Aneeshkumar et al, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Kucik and Clenney, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Leong et al, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Daudia et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Schlosser, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Mulla et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Patel and Fowell, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Womack et al, 2018</a>].</p><h4>Epistaxis in children younger than 2 years of age</h4><ul><li>Epistaxis is rare in children under 2 years of age and an underlying cause such as injury or coagulopathy should, therefore, be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Patel et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Siddiq and Grainger, 2015</a>].</li><li>A retrospective analysis of Accident and Emergency department attendance records and hospital admissions reported 16 cases of nose bleed within this age group. In 8 cases, bleeding was associated with visible trauma; in 4 cases with thrombocytopenia (secondary to malignancy in 3 cases); in 2 cases with an associated apparent life-threatening event; and in 2 cases with an upper respiratory tract infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">McIntosh et al, 2007</a>].</li><li>Epistaxis in children under 2 years of age is significantly associated with asphyxiation (unintentional or intentional). A meta-analysis of four studies found that the probability of asphyxiation in a child under two years old with epistaxis is 19.6% (95% CI, 12.7-28.8%) and described the features associated with asphyxiation for those with epistaxis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">RCPCH, 2017</a>]. </li></ul><h4>Hereditary haemorrhagic telangiectasia</h4><ul><li>The information on the clinical features of hereditary haemorrhagic telangiectasia derives from expert opinion provided on the NHS England website [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">NHS England, 2017</a>].</li></ul><!-- end field 3266158b-4775-404a-89cf-5d7fc9665a48 --><!-- end item 2c7b9551-8b73-47c9-9b29-298728add8b6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}